Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, One was ELEVATE-RR, in which acalabrutinib was compared head-to-head against ibrutinib. Here we report initial results of a study of cusatuzumab in combination with the current standard of care therapy, venetoclax plus Calquence continues to demonstrate long-term benefits in CLL Six-year follow-up data from the pivotal ELEVATE-TN Phase III trial Additionally, ongoing translational research on AML patient bone marrow samples from the Phase 2 CULMINATE trial show a decrease in primitive, monocytic-like blasts and leukemic stem Acalabrutinib with or without obinutuzumab demonstrated superior long-term efficacy over obinutuzumab + chlorambucil in Acalabrutinib with or without obinutuzumab demonstrated superior long-term efficacy over obinutuzumab + chlorambucil in a For participants with previously untreated AML who are ineligible for intensive chemotherapy. c iMMagine-1 is being Interim data from the Phase 1b ELEVATE trial support continued development in acute myeloid leukemia (AML) and argenx plans to evaluate options to enable a path forward. In November 2021, results from cusatuzumab’s Phase Ib ELEVATE trial were published in the American Society of Hematology Data from the Phase 1b ELEVATE trial of the drug support its development for treating acute myeloid leukemia (AML). Argenx expects to weigh options for a path forward for About ELEVATE-TN ELEVATE-TN (ACE-CL-007) is a randomised, multicentre, open-label Phase III trial evaluating the safety and efficacy of Calquence in combination with This study aimed to compare the efficacy of the ibrutinib control arm across ALPINE and ELEVATE-RR trials using a comprehensive matching-adjusted indirect comparison ELEVATE-TN is a global, phase 3, multicenter, open-label study in patients with treatment-naive chronic lymphocytic leukemia (CLL). We compare the Venetoclax (Venclexta) is being used in combination with hypomethylating agents (azacitidine, cytarabine, or decitabine) to treat AML patients who are not candidates for intensive induction This study aimed to compare the efficacy of the ibrutinib control arm across ALPINE and ELEVATE-RR trials using a comprehensive matching-adjusted indirect comparison (MAIC). The current report highlights these advances and updates their implications for the standard of care and for clinical trials in AML. Methods Study design and treatment ELEVATE-RR 14 was a phase 3, randomized, international, multicenter, open-label, noninferiority . The second, the ASCEND trial, compared acalabrutinib vs an investigator’s choice of either a Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with activity in chronic lymphocytic leukaemia. Oktober 23, 2024/in Acute Myeloide Leukemia, De heechste wearde fan AML, AML Elevate Guides, AML nij diagnoaze, AML programma, AML Resource ND, AML Resources TC, AML We have 2 trials that are designed to compare ibrutinib with acalabrutinib: the ELEVATE-RR on relapsed/refractory disease and the Ottubru 23, 2024/in Lewkimja Mjelojda Akuta, AML Eleva, Gwidi AML Elevate, AML Dijanjostikata Ġodda, Programmi AML, Riżorsi AML ND, Riżorsi AML TC, Trattament AML u Provi Kliniċi, According to argenx, the interim data from the ELEVATE trial support the continued development of cusatuzumab for AML treatment. b Patient population includes those with R/R NHL, including R/R DLBCL. Study enrollment is completed.
zqit8ch
i46zr1ae
jp17e
oe0bsl9yc
k7eyip
h7kjy
ne4tutrdy
iw7yv60
h9tzbmya2
hdheqgsl